A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients

Clinical Infectious Diseases

Volumn 39, Issue 4, 2004, Pages 591-594

  Wood, Robin ^a   Eron, Joseph ^g   Arasteh, Keikawus ^b   Teofilo, Eugenio ^c   Trepo, Christian ^d   Livrozet, Jean Michel ^e   Yeo, Jane ^f   Millard, Judith ^g   Wire, Mary Beth ^g   Naderer, Odin J ^g,h  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c Servico de Medicina 3   (Portugal)

^d HÔTEL DIEU   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f GLAXOSMITHKLINE   (United Kingdom)

^g GLAXOSMITHKLINE   (United States)

^h NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; CREATINE KINASE; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; RITONAVIR; TRIACYLGLYCEROL;

ABSCESS; ANOREXIA; ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHODGKIN LYMPHOMA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES;

EID: 4344700080     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422452     Document Type: Article

References (13)

1. Goodgame JC, Pottage JC Jr, Jablonowski H, et al. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1 infected antiretroviral-naive adults. Antivir Ther 2000; 5:215-25.
2. Haubrich R, Thompson M, Schooley R, et al. A phase II safety and efficacy study of APV in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. AIDS 1999; 13:2411-20.
3. Murphy R, Gulick R, DeGruttola V, et al. Treatment with APV alone or APV with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J Infect Dis 1999; 179:808-16.
4. Pedneault, Brothers LC, Pagano G, et al. Safety profile and tolerability of APV in the treatment of adult and pediatric patients with HIV infection. Clin Ther 2000; 22:1378-94.
5. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995; 39:1704-10.
6. Alford JL, McQuiaid TC, Partaledis JA, et al. Amprenavir-resistant mutants show reduced viral fitness: correlation of protease mutations, cleavage site mutations, enzyme kinetics, viral polyprotein processing and viral growth kinetics [abstract 44]. In: Program and abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (San Diego, CA), 1999.
7. Markland W, Zuchowski L, Black J, et al. Kinetic and structural analysis of HIV-1 protease mutations: APV resistance, cross-resistance and resensitisation [abstract 24]. In: Program and abstracts of the 2nd International Workshop on Drug Resistance and Treatment Strategies (Lake Maggiore, Italy), 1998.
8. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42:3218-24.
9. Saag MS, Kilby M, Ehrensing E, Buss N, Oo CY. Modulation of saquinavir steady-state pharmacokinetics with "baby" doses of RTV in healthy volunteers [abstract 829]. In: Program and abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV Infection (Lisbon, Portugal), 1999.
10. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between RTV and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42:2784-91.
11. Sadler B, Pilieor P, Preston S, Lou Y, Sale M, Stein D. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple, oral dosing [abstract 77]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA), 2000.
12. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002; 46:746-54.
13. Wood R, Arasteh K, Stellbrink HJ, et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004; 48:116-23.